At Nemours, we promise to do whatever it takes to treat children as we would our own. When your child comes to Nemours, we know you’re placing your trust in us. This trust and our dedication to improving the health of your child is what inspires us to provide exceptional care and the most satisfying experience possible.
Stories: Patients and families share their experiences.
Quality & Safety: Learn how we track and measure the success of our care.
- Acute Lymphoblastic Leukemia (ALL) Survival Rate
- Giving Even the Sickest Children the Best Chance at Life
Patient Satisfaction: See what families say about our care.
News & Recognition
- Alfred I. duPont Hospital for Children Wins Research Grant From Hyundai Hope On Wheels
- Caitlin Robb Foundation Donates to Cancer Research
- Carper, Carney Announce $4.6 Million for Cancer Research
- Dr. Kolb Appointed to Children's Oncology Group Scientific Council
- Component of Turmeric Shows Promise in Brain Tumor Treatment
- D.O. Believe Foundation Donates $25,000 to Nemours Childhood Cancer Research
- Delaware Health Sciences Alliance Awards Grant to Nemours Center for Childhood Cancer Research
- Hyundai Hope on Wheels Awards Nemours $100,000 Grant
- Jeremy P. Wilson Foundation Donates $20,000 to Nemours Cancer Research
- Joint Cancer Program of Nemours and Wolfson Children's Receives Achievement Award
- Kids' Runway for Research gives $9,000 to Child Cancer Research
- Nanotechnology for Drug Delivery Shows Promise in Treatment of Pediatric Leukemia
- Nemours Receives Donation to Support Cancer Research
- Nemours Researchers Uncover New Evidence of Harmfulness of Secondhand Smoke
- Students Donate Art Work to Nemours/Alfred I. duPont Hospital for Children
- U.S. News & World Report 2011-2012
Nanotechnology for Drug Delivery Shows Promise in Treatment of Pediatric Leukemia
A. K. Rajasekaran, PhD
This month, Molecular Pharmaceutics reported promising findings from the Nemours Center for Childhood Cancer Research and the Materials Science and Engineering Department at the University of Delaware, about the potential for nanotechnology to deliver chemotherapeutic agents in a way that attacks cancer cells without harming healthy cells.
To date, nanoparticle-based drug delivery approaches have been poorly developed for the treatment of childhood leukemia, which comprises 30 percent of childhood cancers. In the Nemours study, encapsulated dexamethasone (“dex”) delivered to pre-clinical models with leukemia significantly improved the quality of life and survival compared to the control receiving the unencapsulated drug.
Acute lymphoblastic leukemia (ALL) is the most common form of pediatric leukemia. Although five-year survival rates for ALL approach 90 percent with available chemotherapy treatments, the harmful side effects of the drugs, including secondary cancers and fertility, cognitive, hearing, and developmental problems, present significant concern for survivors and their families.
Studies conducted by the lead author A. K. Rajasekaran, PhD, and his team at Nemours in collaboration with Xinqiao Jia, PhD, and her team at the University of Delaware, used polymeric nanoparticles containing chemotherapeutic agents to ensure controlled delivery of drugs to cancer cells in preclinical models.
“There are currently seven or eight drugs that are used for chemotherapy to treat leukemia in children,” said Dr. Rajasekaran. “They are all toxic and do their job by killing rapidly dividing cells.” However, he explained, these drugs don’t differentiate cancer cells from other healthy cells. “The good news is that these drugs are 80 to 90 percent effective in curing leukemia. The bad news is that many chemotherapeutic treatments cause severe side effects, especially in children.” He posits that it will take researchers hundreds of millions of dollars and many years to find better alternative drug treatments. In the interim, scientists like Dr. Rajasekaran and his colleagues are working on novel ways to deliver existing and affordable drugs to children.
“Our polymer synthesis and particle engineering are guided by the clinical need for reducing the side effects of cancer drugs,” Dr. Jia commented.
Vinu Krishnan, the first author of the study and a chemical engineer and graduate student in Materials Science and Engineering, said, “I am very excited about the results and look forward to taking this to the next level and introducing this approach for the clinical treatment of childhood leukemia.”
Students in Dr. Jia’s group contributing to this work include Xian Xu and Xiaowei Yang.
To date, advances in nanotechnology have been primarily concentrated around adult cancers. Nanotechnology involves the use of encapsulated particles of drugs that go into the core of the cell. The nanoparticles stick only to the cancer cells and destroy them by delivering the drug precisely, without detecting or harming the normal cells.
In preclinical models of leukemia, Dr. Rajasekaran and his team were able to improve survival and quality of life via nanotechnology. Encapsulating the drug uses one third of the typical dose, with good treatment results and no discernible side effects. In addition, the mice that received the drugs delivered via nanoparticles survived longer than those that received the drug administered in the traditional way.
This work is supported by National Institutes of Health (RO1 DK56216, P20RR016458, P20 RR017716), Delaware Health Sciences Alliance, Andrew McDonough B + Foundation, Caitlin Robb Foundation, Kids Runway for Research, Sones Brothers, Nemours Foundation and funds from the University of Delaware.